ABSTRACT
RATIONALE: Low high-density lipoprotein-cholesterol (HDL-C) in patients with coronary heart disease (CHD) may be caused by rate-limiting amounts of lecithin:cholesterol acyltransferase (LCAT). Raising LCAT may be beneficial for CHD, as well as for familial LCAT deficiency, a rare disorder of low HDL-C. OBJECTIVE: To determine safety and tolerability of recombinant human LCAT infusion in subjects with stable CHD and low HDL-C and its effect on plasma lipoproteins. METHODS AND RESULTS: A phase 1b, open-label, single-dose escalation study was conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human LCAT (ACP-501). Four cohorts with stable CHD and low HDL-C were dosed (0.9, 3.0, 9.0, and 13.5 mg/kg, single 1-hour infusions) and followed up for 28 days. ACP-501 was well tolerated, and there were no serious adverse events. Plasma LCAT concentrations were dose-proportional, increased rapidly, and declined with an apparent terminal half-life of 42 hours. The 0.9-mg/kg dose did not significantly change HDL-C; however, 6 hours after doses of 3.0, 9.0, and 13.5 mg/kg, HDL-C was elevated by 6%, 36%, and 42%, respectively, and remained above baseline ≤4 days. Plasma cholesteryl esters followed a similar time course as HDL-C. ACP-501 infusion rapidly decreased small- and intermediate-sized HDL, whereas large HDL increased. Pre-ß-HDL also rapidly decreased and was undetectable ≤12 hours post ACP-501 infusion. CONCLUSIONS: ACP-501 has an acceptable safety profile after a single intravenous infusion. Lipid and lipoprotein changes indicate that recombinant human LCAT favorably alters HDL metabolism and support recombinant human LCAT use in future clinical trials in CHD and familial LCAT deficiency patients. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01554800.
Subject(s)
Phosphatidylcholine-Sterol O-Acyltransferase/administration & dosage , Phosphatidylcholine-Sterol O-Acyltransferase/blood , Recombinant Proteins/administration & dosage , Recombinant Proteins/blood , Adult , Aged , Aged, 80 and over , Dose-Response Relationship, Drug , Exanthema/chemically induced , Female , Follow-Up Studies , Humans , Male , Middle Aged , Phosphatidylcholine-Sterol O-Acyltransferase/adverse effects , Recombinant Proteins/adverse effectsABSTRACT
Bleomycin-induced lung fibrosis is a debilitating disease, linked to high morbidity and mortality in chemotherapy patients. The MRTF/SRF transcription pathway has been proposed as a potential therapeutic target, as it is critical for myofibroblast differentiation, a hallmark of fibrosis. In human lung fibroblasts, the MRTF/SRF pathway inhibitor, CCG-257081, effectively decreased mRNA levels of downstream genes: smooth muscle actin and connective tissue growth factor, with IC50 s of 4 and 15 µM, respectively. The ability of CCG-257081 to prevent inflammation and fibrosis, measured via pulmonary collagen content and histopathology, was tested in a murine model of bleomycin-induced lung fibrosis. Animals were given intraperitoneal bleomycin for 4 weeks and concurrently dosed with CCG-257081 (0, 10, 30, and 100 mg/kg PO), a clinical anti-fibrotic (nintedanib) or the clinical standard of care (prednisolone). Mice treated with 100 mg/kg CCG-257081 gained weight vs. vehicle-treated control mice, while those receiving nintedanib and prednisolone lost significant weight. Hydroxyproline content and histological findings in tissue of animals on 100 mg/kg CCG-257081 were not significantly different from naive tissue, indicating successful prevention. Measures of tissue fibrosis were comparable between CCG-257081 and nintedanib, but only the MRTF/SRF inhibitor decreased plasminogen activator inhibitor-1 (PAI-1), a marker linked to fibrosis, in bronchoalveolar lavage fluid. In contrast, prednisolone led to marked increases in lung fibrosis by all metrics. This study demonstrates the potential use of MRTF/SRF inhibitors to prevent bleomycin-induced lung fibrosis in a clinically relevant model of the disease.
Subject(s)
Bleomycin , Pulmonary Fibrosis , Humans , Animals , Mice , Bleomycin/toxicity , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/prevention & control , Inflammation , Fibroblasts , PrednisoloneABSTRACT
The design of drugs with selective tissue distribution can be an effective strategy for enhancing efficacy and safety, but understanding the translation of preclinical tissue distribution data to the clinic remains an important challenge. As part of a discovery program to identify next generation liver selective HMG-CoA reductase inhibitors we report the identification of (3R,5R)-7-(4-((3-fluorobenzyl)carbamoyl)-5-cyclopropyl-2-(4-fluorophenyl)-1H-imidazol-1-yl)-3,5-dihydroxyheptanoic acid (26) as a candidate for treating hypercholesterlemia. Clinical evaluation of 26 (PF-03491165), as well as the previously reported 2 (PF-03052334), provided an opportunity for a case study comparison of the preclinical and clinical pharmacokinetics as well as pharmacodynamics of tissue targeted HMG-CoA reductase inhibitors.
Subject(s)
Drug Discovery , Heptanoic Acids/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis , Hypercholesterolemia/drug therapy , Imidazoles/chemical synthesis , Liver/drug effects , Animals , Cells, Cultured , Dogs , Dose-Response Relationship, Drug , Hepatocytes/drug effects , Heptanoic Acids/chemistry , Heptanoic Acids/pharmacokinetics , Heptanoic Acids/pharmacology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Imidazoles/chemistry , Imidazoles/pharmacokinetics , Imidazoles/pharmacology , Inhibitory Concentration 50 , Molecular Structure , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , Rats , Tissue DistributionABSTRACT
Lecithin cholesterol acyl transferase (LCAT) deficiency is associated with low high-density lipoprotein (HDL) and the presence of an abnormal lipoprotein called lipoprotein X (Lp-X) that contributes to end-stage renal disease. We examined the possibility of using LCAT an as enzyme replacement therapy agent by testing the infusion of human recombinant (r)LCAT into several mouse models of LCAT deficiency. Infusion of plasma from human LCAT transgenic mice into LCAT-knockout (KO) mice rapidly increased HDL-cholesterol (C) and lowered cholesterol in fractions containing very-low-density lipoprotein (VLDL) and Lp-X. rLCAT was produced in a stably transfected human embryonic kidney 293f cell line and purified to homogeneity, with a specific activity of 1850 nmol/mg/h. Infusion of rLCAT intravenously, subcutaneously, or intramuscularly into human apoA-I transgenic mice showed a nearly identical effect in increasing HDL-C approximately 2-fold. When rLCAT was intravenously injected into LCAT-KO mice, it showed a similar effect as plasma from human LCAT transgenic mice in correcting the abnormal lipoprotein profile, but it had a considerably shorter half-life of approximately 1.23 ± 0.63 versus 8.29 ± 1.82 h for the plasma infusion. rLCAT intravenously injected in LCAT-KO mice crossed with human apolipoprotein (apo)A-I transgenic mice had a half-life of 7.39 ± 2.1 h and increased HDL-C more than 8-fold. rLCAT treatment of LCAT-KO mice was found to increase cholesterol efflux to HDL isolated from mice when added to cells transfected with either ATP-binding cassette (ABC) transporter A1 or ABCG1. In summary, rLCAT treatment rapidly restored the normal lipoprotein phenotype in LCAT-KO mice and increased cholesterol efflux, suggesting the possibility of using rLCAT as an enzyme replacement therapy agent for LCAT deficiency.
Subject(s)
Lipoproteins/metabolism , Phosphatidylcholine-Sterol O-Acyltransferase/pharmacology , Animals , Apolipoproteins E/metabolism , Cholesterol/metabolism , Cholesterol Esters/metabolism , Cricetinae , Humans , Infusions, Intravenous , Lipid Metabolism/drug effects , Lipoproteins, VLDL/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Phosphatidylcholine-Sterol O-Acyltransferase/administration & dosage , Phosphatidylcholine-Sterol O-Acyltransferase/genetics , Recombinant ProteinsABSTRACT
Peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid and glucose metabolism. PPARgamma agonists improve insulin sensitivity and hyperglycemia and are effective in treating type 2 diabetes mellitus (T2DM), whereas PPARalpha agonists are used to treat dyslipidemia and atherosclerosis. The goal here was to examine the efficacy of a selective PPARalpha agonist {(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-trifluoromethyl-benzyl ester; CP-900691} on lipid, glycemic, and inflammation indices in 14 cynomolgus monkeys with spontaneous T2DM maintained on daily insulin therapy. Monkeys were dosed orally with either vehicle (n = 7) or CP-900691 (3 mg/kg, n = 7) daily for 6 weeks. CP-900691 treatment increased plasma high-density lipoprotein cholesterol (HDLC) (33 +/- 3 to 60 +/- 4 mg/dL, p < 0.001) and apolipoprotein A1 (96 +/- 5 to 157 +/- 5 mg/dL, p < 0.001), reduced plasma triglycerides (547 +/- 102 to 356 +/- 90 mg/dL, p < 0.01), and apolipoprotein B (62 +/- 3 to 45 +/- 3 mg/dL, p < 0.01), improved the lipoprotein index (HDL to non-HDLC ratio; 0.28 +/- 0.06 to 0.79 +/- 0.16, p < 0.001), decreased body weight (p < 0.01) and C-reactive protein (CRP) (1700 +/- 382 to 304 +/- 102 ng/ml, p < 0.01), and increased adiponectin (1697 +/- 542 to 4242 +/- 1070 ng/ml, p < 0.001) compared with baseline. CP-900691 treatment reduced exogenous insulin requirements by approximately 25% (p < 0.04) while lowering plasma fructosamine from 2.87 +/- 0.09 to 2.22 +/- 0.17 mM (p < 0.05), indicative of improved glycemic control. There were no changes in any of the aforementioned parameters in the vehicle group. Because low HDLC and high triglycerides are well established risk factors for cardiovascular disease, the marked improvements in these parameters, and in glycemic control, body weight, and CRP, suggest that CP-900691 may be of benefit in diabetic and obese or hyperlipidemic populations.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/pharmacology , Hypolipidemic Agents , Lipids/blood , Lipoproteins/blood , PPAR alpha/agonists , Piperidines/pharmacology , Propionates/pharmacology , Adiponectin/blood , Animals , Area Under Curve , C-Reactive Protein/metabolism , Diabetes Mellitus, Type 2/genetics , Dose-Response Relationship, Drug , Glucose Tolerance Test , Insulin Resistance , Macaca fascicularis , Weight Loss/drug effectsABSTRACT
Cannabinoid-1 (CB(1)) receptor antagonists exhibit pharmacological properties favorable to treatment of obesity, caused by both centrally mediated effects on appetite and peripherally mediated effects on energy metabolism. However, the relative contribution of these effects to the weight loss produced by CB(1) receptor antagonists remains unclear. Here, we compare food intake-related and independent effects of the CB(1)-selective antagonist 1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-3-(methylamino) azetidine-3-carboxamide (PF-95453) in obese cynomolgus monkeys. Monkeys were divided into three study groups (n = 10 each) and treated once daily for 8 weeks with either vehicle or PF-95453 as follows: 1, fed ad libitum and dosed orally with vehicle; 2, fed ad libitum and dosed orally with PF-95453 (0.5 mg/kg weeks 1-3, 1.0 mg/kg weeks 4-8); and 3, fed an amount equal to the amount consumed by the drug-treated group and dosed orally with vehicle (pair-fed). PF-95453 treatment significantly reduced food consumption by 23%, body weight by 10%, body fat by 39%, and leptin by 34% while increasing adiponectin by 78% relative to vehicle-treated controls. Pair-fed animals did not exhibit reductions in body weight or leptin but did show significantly reduced body fat (11%) and increased adiponectin (15%) relative to vehicle-treated controls but markedly less than after PF-95453 treatment. Indeed, significant differences were noted between the drug-treated and pair-fed groups with respect to body weight reduction, body fat reduction, increased adiponectin, and leptin reduction. Similar to humans, monkeys treated with the CB(1) receptor antagonist exhibited decreased body weight and body fat, a substantial portion of which seemed to be independent of the effects on food intake.
Subject(s)
Adiposity/drug effects , Anti-Obesity Agents , Azetidines/pharmacology , Body Composition/drug effects , Body Weight/drug effects , Obesity/drug therapy , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Triazines/pharmacology , Adiponectin/metabolism , Animals , Azetidines/pharmacokinetics , Blood Glucose/metabolism , Diet , Dogs , Dose-Response Relationship, Drug , Eating/drug effects , Eating/physiology , Endpoint Determination , Feeding Behavior/drug effects , Glucose Tolerance Test , Leptin/metabolism , Lipids/blood , Macaca fascicularis , Male , Rats , Rats, Sprague-Dawley , Triazines/pharmacokinetics , Weight Loss/drug effectsABSTRACT
BACKGROUND: Information technology improves outcomes (e.g., by reducing error), and universal implementation of electronic medical records throughout the United States is a national goal. Prior studies have shown low rates of implementation. OBJECTIVES: To assess the current state of acquisition and implementation of information technology tools in Massachusetts emergency departments (EDs). METHODS: This was part of a larger survey that sought to describe various attributes of all non-federal Massachusetts EDs. We asked about implementation of technologies listed below, and report proportions (95% confidence intervals) and medians (interquartile ranges). We compare responding to non-responding EDs to guard against response bias. RESULTS: We identified and surveyed 74 non-federal EDs; 61 (82%) responded. Of these, the following number (%) reported full implementation of the following technologies: medication ordering, 9 (15%); medication error checking, 7 (11%); current visit information (e.g., chief complaint), 25 (41%); computerized management recommendations based on clinical decision rules, 6 (10%); electronic laboratory results, 55 (90%); computerized clinical reminders, 10 (17%); tracking information, 31 (51%); hospital discharge summaries, 50 (82%); current outpatient medications, 15 (25%); ED visit notes, 30 (49%); radiographic images from a prior visit, 39 (64%); old electrocardiograms, 33 (54%); and computer system to collect real-time clinical data, 23 (38%). CONCLUSION: Massachusetts EDs have been slow to adopt evidence-based information technologies. A collaborative approach to determining the best available technologies and their implementation would decrease duplication of effort, frustration, and financial waste (due to non-implementation of acquired systems), and would facilitate inter-operability of ED computer systems.
Subject(s)
Decision Support Systems, Clinical/statistics & numerical data , Electronic Health Records/statistics & numerical data , Emergency Service, Hospital , Medical Order Entry Systems/statistics & numerical data , Data Collection , Humans , MassachusettsABSTRACT
INTRODUCTION: As Hurricane Katrina bore down on New Orleans in August 2005, the city's mandatory evacuation prompted the exodus of an estimated 80% of its 485,000 residents. According to estimates from the US Centers for Disease Control and Prevention (CDC), at least 18 states subsequently hosted more than 200,000 evacuees. HYPOTHESIS/PROBLEM: In this case study, "Operation Helping Hands" (OHH), the Massachusetts health and medical response in assisting Hurricane Katrina evacuees is described. Operation Helping Hands represents the largest medical response to evacuees in recent Massachusetts history. METHODS: The data describing OHH were derived from a series of structured interviews conducted with two leading public health officials directing planning efforts, and a sample of first responders with oversight of operations at the evacuation site. Also, a literature review was conducted to identify similar experiences, common challenges, and lessons learned. RESULTS: Activities and services were provided in the following areas: (1) administration and management; (2) medical and mental health; (3) public health; and (4) social support. This study adds to the knowledge base for future evacuation and shelter planning, and presents a conceptual framework that could be used by other researchers and practitioners to describe the process and outcomes of similar operations. CONCLUSIONS: This study provides a description of the planning and implementation efforts of the largest medical evacuee experience in recent Massachusetts history, an effort that involved multiple agencies and partners. The conceptual framework can inform future evacuation and shelter initiatives at the state and national levels, and promotes the overarching public health goal of the highest attainable standard of health for all.
Subject(s)
Cyclonic Storms , Delivery of Health Care/organization & administration , Disaster Planning/organization & administration , Relief Work/organization & administration , Emergency Service, Hospital/organization & administration , Humans , Massachusetts , Public Health , Triage/organization & administrationABSTRACT
The synthesis of a new series of phenylpropanoic acid derivatives incorporating an heteroaryl group at the alpha-position and their evaluation for binding and activation of PPARalpha and PPARgamma are presented in this report. Among the new compounds, (S)-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3-triazol-2-yl-propionic acid (17j), was identified as a potent human PPARalpha/gamma dual agonist (EC(50)=0.013 and 0.061 microM, respectively) with demonstrated oral bioavailability in rat and dog. 17j was shown to decrease insulin levels, plasma glucose, and triglycerides in the ZDF female rat model. In the human apolipoprotein A-1/CETP transgenic mouse model 17j produced increases in hApoA1 and HDL-C and decreases in plasma triglycerides. The increased potency for binding and activation of both PPAR subtypes observed with 17j when compared to previous analogs in this series was explained based on results derived from crystallographic and modeling studies.
Subject(s)
PPAR alpha/agonists , PPAR gamma/agonists , Propionates/chemical synthesis , Propionates/pharmacology , Animals , Biological Availability , Blood Glucose/analysis , Crystallography, X-Ray , Dogs , Drug Evaluation, Preclinical , Female , Insulin/blood , Magnetic Resonance Spectroscopy , Mass Spectrometry , Mice , Mice, Transgenic , Propionates/pharmacokinetics , Rats , Triglycerides/bloodABSTRACT
In light of accumulating evidence that aggressive LDL-lowering therapy may offer increased protection against coronary heart disease, we undertook the design and synthesis of a novel series of HMG-CoA reductase inhibitors based upon a substituted pyrazole template. Optimizing this series using both structure-based design and molecular property considerations afforded a class of highly efficacious and hepatoselective inhibitors resulting in the identification of (3 R,5 R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Subject(s)
Heptanoic Acids/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis , Hypercholesterolemia/drug therapy , Liver/drug effects , Pyrazoles/chemical synthesis , Animals , Cholesterol, LDL/biosynthesis , Cholesterol, LDL/blood , Cricetinae , Guinea Pigs , Hepatocytes/drug effects , Hepatocytes/metabolism , Heptanoic Acids/chemistry , Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , In Vitro Techniques , Liver/metabolism , Male , Mesocricetus , Muscle Cells/drug effects , Muscle Cells/metabolism , Pyrazoles/chemistry , Pyrazoles/pharmacology , Rats , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Cholesterol absorption inhibition (CAI) represents an important treatment option for hypercholesterolemia. Herein, we report the design and evaluation of a series of substituted oxazolidinones as ligands for the Niemann Pick C1 Like 1 (NPC1L1) protein, a key mediator of cholesterol transport. Novel analogs were initially evaluated in a brush border membrane NPC1L1 binding assay; subsequently, promising compounds were evaluated in vivo for acute inhibition of cholesterol absorption. These studies identified analogs with low micromolar NPC1L1 binding affinity and acute in vivo efficacy of >50% absorption inhibition at 3mg/kg.
Subject(s)
Cholesterol/metabolism , Intestinal Absorption/drug effects , Membrane Transport Proteins/metabolism , Oxazolidinones/pharmacology , Animals , Ligands , Microvilli/metabolism , Oxazolidinones/chemistry , Oxazolidinones/metabolism , Oxazolidinones/pharmacokinetics , Rats , X-Ray DiffractionABSTRACT
4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Muscle Cells/drug effects , Pyrroles/chemical synthesis , Pyrroles/pharmacology , Sulfonamides/chemical synthesis , Sulfonamides/pharmacology , Animals , Atorvastatin , Combinatorial Chemistry Techniques , Disease Models, Animal , Fluorobenzenes/pharmacology , Hepatocytes/drug effects , Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry , Mice , Molecular Structure , Pyrimidines/pharmacology , Pyrroles/chemistry , Rosuvastatin CalciumABSTRACT
A new series of alpha-aryl or alpha-heteroarylphenyl propanoic acid derivatives was synthesized that incorporate acetylene-, ethylene-, propyl-, or nitrogen-derived linkers as a replacement of the commonly used ether moiety that joins the central phenyl ring with the lipophilic tail. The effect of these modifications in the binding and activation of PPARalpha and PPARgamma was first evaluated in vitro. Compounds possessing suitable profiles were then evaluated in the ob/ob mouse model of type 2 diabetes. The propylene derivative 40 and the propyl derivative 53 demonstrated robust plasma glucose lowering activity in this model. Compound 53 was also evaluated in male Zucker diabetic fatty rats and was found to achieve normalization of glucose, triglycerides, and insulin levels. An X-ray crystal structure of the complex of 53 with the PPARgamma-ligand-binding domain was obtained and discussed in this report.
Subject(s)
PPAR alpha/agonists , PPAR gamma/agonists , Phenylpropionates , Administration, Oral , Animals , Crystallography, X-Ray , Disease Models, Animal , Male , Mice , Mice, Obese , Models, Molecular , Molecular Structure , Phenylpropionates/chemical synthesis , Phenylpropionates/chemistry , Phenylpropionates/pharmacology , Rats , Rats, Sprague-Dawley , Rats, Zucker , Stereoisomerism , Structure-Activity RelationshipABSTRACT
STUDY OBJECTIVE: Emergency departments (EDs) provide round-the-clock emergency care but also serve as a health care "safety net." We seek to determine the number, distribution, and characteristics of US EDs, with a long-term goal of improving access to emergency care. METHODS: We created an inventory of nonfederal nonspecialty US hospitals using 2001 data from 2 independent sources. Hospitals that did not report ED visit data, or with large changes in visit volume by 2003, were contacted to obtain or verify visit volume (n=437; 9% of all hospitals). EDs were divided into 2 groups: those with at least 1 patient per hour, 24 hours per day, 7 days per week (> or = 8,760 visits/year) and those with fewer visits. RESULTS: Of 4,917 hospitals, 4,862 (99%) reported an ED. These EDs collectively received 101.6 million visits. One in 3 EDs (n=1,535) received less than 8,760 visits per year; the national median was 15,711 visits per year. Excluding the low-volume EDs, the remaining 3,327 reported 95.2 million annual visits. The typical higher-volume ED received approximately 28,000 visits per year; 28% (n=922) were in a nonurban setting. Among all EDs, per-capita visits varied by state, with the highest ED visit rates in Washington, DC; West Virginia; and Mississippi. CONCLUSION: Significant variation exists in the distribution and use of US EDs. One third of EDs have an annual visit volume less than 8,760 and, together, they account for 6% of all visits. The United States should consider classifying EDs, as it does trauma centers, to clarify the type of care available in this heterogeneous clinical setting and the distribution of different types of EDs.
Subject(s)
Emergency Service, Hospital/statistics & numerical data , Outpatient Clinics, Hospital/statistics & numerical data , Databases, Factual , Humans , Internship and Residency/statistics & numerical data , Rural Population , United States , Urban PopulationABSTRACT
Type 2 diabetes mellitus is a major health problem of increasing incidence. To better study the pathogenesis and potential therapeutic agents for this disease, appropriate animal models are needed. Old World nonhuman primates (NHPs) are a useful animal model of type 2 diabetes; like humans, the disease is most common in older, obese animals. Before developing overt diabetes, NHPs have a period of obesity-associated insulin resistance that is initially met with compensatory insulin secretion. When either a relative or absolute deficiency in pancreatic insulin production occurs, fasting glucose concentrations begin to increase and diabetic signs become apparent. Pathological changes in pancreatic islets are also similar to those seen in human diabetics. Initially there is hyperplasia of the islets with abundant insulin production typically followed by replacement of islets with islet-associated amyloid. Diabetic NHPs have detrimental changes in plasma lipid and lipoprotein concentrations, lipoprotein composition, and glycation, which may contribute to progression of atherosclerosis. As both the prediabetic condition (similar to metabolic syndrome in humans) and overt diabetes become better defined in monkeys, their use in pharmacological studies is increasing. Likely due to their genetic similarity to humans and the similar characteristics of the disease in NHPs, NHPs have been used to study recently developed agonists of the peroxisome proliferators-activated receptors. Importantly, agonists of the different receptor subclasses elicit similar responses in both humans and NHPs. Thus, Old World NHPs are a valuable animal model of type 2 diabetes to study disease progression, associated risk factors, and potential new treatments.
Subject(s)
Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/veterinary , Disease Models, Animal , Monkey Diseases/metabolism , Prediabetic State/veterinary , Animals , Cercopithecidae , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/physiopathology , Female , Hypoglycemic Agents/therapeutic use , Insulin Resistance/physiology , Male , Monkey Diseases/drug therapy , Monkey Diseases/physiopathology , Prediabetic State/metabolism , Prediabetic State/physiopathologyABSTRACT
BACKGROUND: Humans with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) have extremely low or undetectable high-density lipoprotein cholesterol (HDL-C) levels and by early adulthood develop many manifestations of the disorder, including corneal opacities, anemia, and renal disease. OBJECTIVE: To determine if infusions of recombinant human LCAT (rhLCAT) could reverse the anemia, halt progression of renal disease, and normalize HDL in FLD. METHODS: rhLCAT (ACP-501) was infused intravenously over 1 hour on 3 occasions in a dose optimization phase (0.3, 3.0, and 9.0 mg/kg), then 3.0 or 9.0 mg/kg every 1 to 2 weeks for 7 months in a maintenance phase. Plasma lipoproteins, lipids, LCAT levels, and several measures of renal function and other clinical labs were monitored. RESULTS: LCAT concentration peaked at the end of each infusion and decreased to near baseline over 7 days. Renal function generally stabilized or improved and the anemia improved. After infusion, HDL-C rapidly increased, peaking near normal in 8 to 12 hours; analysis of HDL particles by various methods all revealed rapid sequential disappearance of preß-HDL and small α-4 HDL and appearance of normal α-HDL. Low-density lipoprotein cholesterol increased more slowly than HDL-C. Of note, triglyceride routinely decreased after meals after infusion, in contrast to the usual postprandial increase in the absence of rhLCAT infusion. CONCLUSIONS: rhLCAT infusions were well tolerated in this first-in-human study in FLD; the anemia improved, as did most parameters related to renal function in spite of advanced disease. Plasma lipids transiently normalized, and there was rapid sequential conversion of small preß-HDL particles to mature spherical α-HDL particles.
Subject(s)
Lecithin Cholesterol Acyltransferase Deficiency/drug therapy , Phosphatidylcholine-Sterol O-Acyltransferase/therapeutic use , Anemia/complications , Cholesterol, HDL/blood , Disease Progression , Hematologic Tests , Humans , Kidney/drug effects , Lecithin Cholesterol Acyltransferase Deficiency/blood , Lecithin Cholesterol Acyltransferase Deficiency/complications , Lecithin Cholesterol Acyltransferase Deficiency/enzymology , Male , Middle Aged , Phosphatidylcholine-Sterol O-Acyltransferase/adverse effects , Phosphatidylcholine-Sterol O-Acyltransferase/pharmacokinetics , Phosphatidylcholine-Sterol O-Acyltransferase/pharmacology , Recombinant Proteins/adverse effects , Recombinant Proteins/pharmacokinetics , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , SafetyABSTRACT
OBJECTIVE: To examine trends in career satisfaction among physicians working with managed care plans. STUDY DESIGN: Cross-sectional surveys conducted in 1996 and 1999. PARTICIPANTS AND METHODS: We surveyed primary care physicians (PCPs) affiliated with 5 large health plans in Massachusetts and assessed physicians' ratings of overall satisfaction with their current practice situation and with managed care. RESULTS: A total of 1336 PCPs (56%) responded to the 1996 survey and 966 (42%) responded to the 1999 survey. In 1996, 19.8% of physicians were somewhat or very dissatisfied with their current practice situation vs 33.4% in 1999, an increase of more than 50% (P < .001). Overall dissatisfaction with managed care increased from 28.3% to 62.2% (P < .001). In multivariable models, external influences on physicians' practices were important predictors of overall dissatisfaction. Physicians whose choice of hospitals was restricted (odds ratio, 2.23; 95% confidence interval, 1.30-3.78) and those who reported that managed care plans influenced their practice "a lot" (odds ratio, 1.85; 95% confidence interval, 1.10-3.11) were more likely to be dissatisfied. Adequacy of reimbursement was an important predictor of overall satisfaction and satisfaction with managed care, and ways physicians experienced financial incentives were associated with managed care dissatisfaction. CONCLUSIONS: Primary care physicians in Massachusetts are increasingly dissatisfied with their practice and with managed care. Continued erosion of physician satisfaction could have significant implications for quality of care and the quality of the workforce attracted to medicine as a career.
Subject(s)
Attitude of Health Personnel , Job Satisfaction , Physicians, Family/psychology , Female , Health Services Research , Humans , Male , Massachusetts , Multivariate AnalysisSubject(s)
Disaster Planning/methods , Disaster Planning/organization & administration , Emergencies , Public Health Practice , Communicable Disease Control/organization & administration , Communication , Humans , Leadership , Program Development , Program Evaluation , Sentinel Surveillance , United StatesABSTRACT
Launched in 2009, the State Action on Avoidable Rehospitalizations initiative, known as STAAR, aims to reduce rates of avoidable rehospitalization in Massachusetts, Michigan, Ohio, and Washington by mobilizing state-level leadership to improve care transitions. With the program two years into its four-year cycle, 148 hospitals are working in partnership with more than 500 cross-continuum team partners. Although there are no publicly available data on whether the project is achieving its primary goal of reducing avoidable rehospitalizations, the effort has so far been successful in aligning numerous complementary initiatives within a state, developing statewide rehospitalization data reports, and mobilizing a sizable number of hospitals to work on reducing rehospitalizations. More than 90 percent of participating hospitals have formed teams to routinely review rehospitalizations with their community-based colleagues.
Subject(s)
Cost Savings , Health Care Reform/organization & administration , Hospital Costs , Patient Readmission/economics , State Health Plans/organization & administration , Delivery of Health Care/organization & administration , Female , Humans , Male , Massachusetts , Michigan , Ohio , Patient Readmission/statistics & numerical data , Program Development , Program Evaluation , WashingtonABSTRACT
Using structure-based design, a novel series of conformationally restricted, pyrrole-based inhibitors of HMG-CoA reductase were discovered. Leading analogs demonstrated potent inhibition of cholesterol synthesis in both in vitro and in vivo models and may be useful for the treatment of hypercholesterolemia and related lipid disorders.